2018
DOI: 10.5812/hepatmon.82345
|View full text |Cite
|
Sign up to set email alerts
|

PIB: A Score to Select Sorafenib Treatment Candidates for Hepatocellular Carcinoma in Resource-Limited Settings

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 6 publications
(10 reference statements)
0
1
0
Order By: Relevance
“…36 Much lower cutoffs (FLI ≥ 20 to 30) have been used in Asian cohorts. [37][38][39] Thus, it is likely that our high FLI groups include most participants with liver steatosis or fibrosis in both FINRISK cohorts, but the low FLI group also likely includes participants with lowgrade steatosis.…”
Section: Discussionmentioning
confidence: 99%
“…36 Much lower cutoffs (FLI ≥ 20 to 30) have been used in Asian cohorts. [37][38][39] Thus, it is likely that our high FLI groups include most participants with liver steatosis or fibrosis in both FINRISK cohorts, but the low FLI group also likely includes participants with lowgrade steatosis.…”
Section: Discussionmentioning
confidence: 99%